FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140814892> ?p ?o ?g. }

• W2140814892 endingPage "L985" @default.
• W2140814892 startingPage "L984" @default.
• W2140814892 abstract "EDITORIAL FOCUSNew role for glycocalyx in lungAubrey E. TaylorAubrey E. TaylorDepartment of Physiology, University of South Alabama, Mobile, Alabama 36688Published Online:01 Nov 2003https://doi.org/10.1152/ajplung.00165.2003MoreSectionsPDF (39 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInEmail the report by Dull et al., the current article in focus (Ref. 1, see in this issue), evaluates the effect of different polymers of arginine and lysine as models of neutrophil-derived inflammatory proteins. Their size and concentration responses on bovine cultured lung microvascular cells were studied relative to their ability to increase monolayer permeability. Arginine and lysine polymers >11 kDa caused endothelial barrier dysfunction as measured by a 70% decrease in transendothelial electrical resistance (TER), and, in addition, a specific enzyme that removed glycosaminoglycan receptors using a specific enzyme, heparinase III, decreased endothelial damage by 50%, but heparinase I produced no effect. The authors postulated from these studies that changes in actin organization and syndecan localization are responsible for the observed change in membrane permeability, since clustering of syndecans was attenuated by heparinase III. However, ML-7, which inhibits myosin light chain kinase, or a p38 MAPK inhibitor, failed to alter the damage of the endothelial barrier. The conclusion from this study is that endothelial cell heparan sulfate proteoglycans are key participants in inflammatory cationic signaling cytoskeleton reorganization and barrier dysfunction.For several years, we have known that ischemiareperfusion (I/R) or sepsis causes the release of cytokines by activated cells, and their release of IL-1, TNF-α, ICAM-1, and a large number of other factors as well as cells somehow results in damage to the endothelial barrier of lungs (1a-5). What is the physiological and cellular biological importance of this phenomenon? Dull et al. (1) clearly show that heparan sulfate proteoglycans are important components of the cationic peptides that induce signaling, linking the cytoskeleton to barrier dysfunction in endothelial cell monolayers.Because blocking TNF-α, ICAM-1, etc., by pretreatment with specific antibodies inhibits or alters sepsis and I/R endothelial damage, it appears, then, that cytokines may also behave in a fashion to cause the cytoskeleton to reorganize and the endothelial barriers to become more porous and leaky to plasma fluid and proteins (5). The use of TER certainly provides a unique technique that can be used to quantitate endothelial damage in monolayers, but we do not know the relationship between TER and barrier pore size changes, i.e., can TER be related to either protein leakage or fluid leakage or both? Can studies similar to Dull et al. (1) be done in isolated lungs to evaluate the pathophysiology and structural changes in inflammation by measuring TER across the alveolar capillary barrier in fluid-filled lungs? It appears that the approaches used in Dull et al. can be useful tools in intact lung studies and will most likely provide new insight into the structural changes that occur in endothelial and epithelial barriers of lungs during the inflammatory response.However, one could certainly conduct dose-responses curves of different cytokines known to cause disruption of biological barriers as measured with TER to prove that the cationic effect observed in Dull et al. (1) is a specific mechanism used by specific cytokines to induce endothelial contraction and subsequent junctional disruption in sepsis and I/R. A large number of cytokines are known to be released during the immune response in lungs, yet we have not extended our knowledge of how these cytokines, beyond their involvement in several types of inflammatory and anti-inflammatory conditions, upregulate receptors that result in the pathophysiological process, changes seen in lung sepsis and inflammation associated with barrier disruption.The interaction of the glycocalyx, as shown in Dull et al. (1), may likely provide the key to understanding how the inflammatory process occurs or does not occur when lungs are challenged by I/R and sepsis. However, one negative caveat could be that the in vivo endothelial barrier may not behave in the same fashion as found in endothelial monolayers. It is well known that endothelial cells in specific organs and different species certainly have developed immunological characteristics over the years that are related to their environments and produce inherent immune responses that are a product of both their past and present immune histories. But, it is very clear from the results in Dull et al. (1) that reorganization of the cytoskeleton of endothelial monolayers is affected by syndecan clustering, which causes the endothelial barrier permeability to be increased in a manner quite similar to that observed in many sepsis and I/R models of lung inflammation. We are often inclined to complicate a system when it may be as simple as a charge phenomenon that may cause the clustering of syndecans rather than produce up-regulation of receptors on certain sites that cause the effect, and that is what makes this paper interesting and important to the scientific community. References 1 Dull RO, Dinavahi R, Schwartz L, Humphries DE, Berry D, Sasisekharan R, and Garcia JGN. Lung endothelial heparan sulfates mediate cationic peptide-induced barrier dysfunction: a new role for the glycocalyx. Am J Physiol Lung Cell Mol Physiol 285: L986-L995, 2003.Link | ISI | Google Scholar1a Janeway CA, Travers P, Walport M, and Shlomchik M. Immune Biology: The Immune System in Health and Disease (5th ed.). New York: Garland, 2001.Google Scholar2 Levy MM and Vincent JL. Sepsis: Pathophysiologic Insights and Current Management. Proc SCCM/ESICM: Summer Conf, 2003.Google Scholar3 Moore TM, Shirah WB, Khimenko PL, Paisley P, Lausch RN, and Taylor AE. Involvement of CD40-CD40L signaling in postischemic lung injury. Am J Physiol Lung Cell Mol Physiol 283: L1255-L1262, 2002.Link | ISI | Google Scholar4 Nasraway SA. The problems and challenges of immunotherapy in sepsis. Chest 123: 451S-459S, 2003.Crossref | PubMed | ISI | Google Scholar5 Strieter RM, Kunkel SL, and Standiford TJ. Chemokines in the Lung: Lung Biology in Health and Disease. New York: Dekker, 2003.Google ScholarAUTHOR NOTES Address for reprint requests and other correspondence: A. E. Taylor, Dept. of Physiology, MSB 3074, Univ. of South Alabama, Mobile, AL 36688 (E-mail: [email protected]). Previous Back to Top Next FiguresReferencesRelatedInformationCited BySepsis and Major Abdominal Surgery Lead to Flaking of the Endothelial GlycocalixJournal of Surgical Research, Vol. 165, No. 1Contrasting Effects of Colloid and Crystalloid Resuscitation Fluids on Cardiac Vascular PermeabilityAnesthesiology, Vol. 104, No. 6Fullerene derivatives protect against oxidative stress in murine macrophage line cells and ischemia-reperfused lungsAubrey E. Taylor1 July 2004 | American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, Vol. 287, No. 1 More from this issue > Volume 285Issue 5November 2003Pages L984-L985 Copyright & PermissionsCopyright © 2003 the American Physiological Societyhttps://doi.org/10.1152/ajplung.00165.2003PubMed14551039History Published online 1 November 2003 Published in print 1 November 2003 PDF download Metrics Downloaded 142 times" @default.
• W2140814892 created "2016-06-24" @default.
• W2140814892 creator A5047806408 @default.
• W2140814892 date "2003-11-01" @default.
• W2140814892 modified "2023-09-27" @default.
• W2140814892 title "New role for glycocalyx in lung" @default.
• W2140814892 cites W1579751283 @default.
• W2140814892 cites W2112823071 @default.
• W2140814892 cites W2113823462 @default.
• W2140814892 cites W2153978059 @default.
• W2140814892 doi "https://doi.org/10.1152/ajplung.00165.2003" @default.
• W2140814892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14551039" @default.
• W2140814892 hasPublicationYear "2003" @default.
• W2140814892 type Work @default.
• W2140814892 sameAs 2140814892 @default.
• W2140814892 citedByCount "2" @default.
• W2140814892 crossrefType "journal-article" @default.
• W2140814892 hasAuthorship W2140814892A5047806408 @default.
• W2140814892 hasConcept C126322002 @default.
• W2140814892 hasConcept C203014093 @default.
• W2140814892 hasConcept C2777714996 @default.
• W2140814892 hasConcept C2780098789 @default.
• W2140814892 hasConcept C41008148 @default.
• W2140814892 hasConcept C71924100 @default.
• W2140814892 hasConceptScore W2140814892C126322002 @default.
• W2140814892 hasConceptScore W2140814892C203014093 @default.
• W2140814892 hasConceptScore W2140814892C2777714996 @default.
• W2140814892 hasConceptScore W2140814892C2780098789 @default.
• W2140814892 hasConceptScore W2140814892C41008148 @default.
• W2140814892 hasConceptScore W2140814892C71924100 @default.
• W2140814892 hasIssue "5" @default.
• W2140814892 hasLocation W21408148921 @default.
• W2140814892 hasLocation W21408148922 @default.
• W2140814892 hasOpenAccess W2140814892 @default.
• W2140814892 hasPrimaryLocation W21408148921 @default.
• W2140814892 hasRelatedWork W2007746127 @default.
• W2140814892 hasRelatedWork W2420746378 @default.
• W2140814892 hasRelatedWork W2574674283 @default.
• W2140814892 hasRelatedWork W2748952813 @default.
• W2140814892 hasRelatedWork W2780028606 @default.
• W2140814892 hasRelatedWork W2899084033 @default.
• W2140814892 hasRelatedWork W3005066209 @default.
• W2140814892 hasRelatedWork W3005652238 @default.
• W2140814892 hasRelatedWork W3030673248 @default.
• W2140814892 hasRelatedWork W4240407444 @default.
• W2140814892 hasVolume "285" @default.
• W2140814892 isParatext "false" @default.
• W2140814892 isRetracted "false" @default.
• W2140814892 magId "2140814892" @default.
• W2140814892 workType "article" @default.